Immunogen Inc $ 8.75 -0.03 (-0.34%)
Volume:
1,643,190
Avg Vol (1m):
2,783,122
Market Cap $:
1.70 Bil
Enterprise Value $:
1.54 Bil
PE Ratio:
0.00
PB Ratio:
18.66
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | No Debt | ||
| Equity-to-Asset | 0.25 | ||
| Debt-to-EBITDA | -1.26 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | -3.88 | ||
| Beneish M-Score | 33.88 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -15.79 | ||
| Net Margin % | -33.54 | ||
| ROA % | -15.77 | ||
| ROC (Joel Greenblatt) % | -96.49 | ||
| 3-Year Revenue Growth Rate | -7 | ||
| 3-Year EBITDA Growth Rate | 25.8 | ||
| 3-Year EPS without NRI Growth Rate | 25.2 |
IMGN
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 18.66 | ||
| PS Ratio | 12.17 | ||
| EV-to-EBIT | -72.75 | ||
| EV-to-EBITDA | -78.58 | ||
| EV-to-Revenue | 11.64 | ||
| Current Ratio | 2.4 | ||
| Quick Ratio | 2.4 | ||
| Days Sales Outstanding | 13.93 | ||
| Days Payable | 28.39 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 18.62 | ||
| Price-to-Median-PS-Value | 1.26 | ||
| Earnings Yield (Greenblatt) % | -1.37 |